research use only
Cat.No.S2115
| Related Targets | VEGFR PDGFR FGFR c-Met Src MEK CSF-1R FLT3 HER2 c-Kit |
|---|---|
| Other EGFR Inhibitors | Lazertinib (YH25448) Icotinib Hydrochloride Sunvozertinib AG-490 AG-1478 Canertinib (CI-1033) WZ4002 Rociletinib (CO-1686) Poziotinib (NOV120101, HM781-36B) Genistein |
| Molecular Weight | 266.29 | Formula | C16H14N2O2
|
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 136831-48-6 | -- | Storage of Stock Solutions |
|
|
| Synonyms | Tyrphostin RG13022 | Smiles | COC1=C(C=C(C=C1)C=C(C#N)C2=CN=CC=C2)OC | ||
|
In vitro |
DMSO
: 53 mg/mL
(199.03 mM)
Ethanol : 5 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Targets/IC50/Ki |
EGFR
(Cell-free assay) 4 μM
|
|---|---|
| In vitro |
RG-13022 inhibits autophosphorylation of the EGF-receptor in HER 14 cells after an overnight incubation. The IC50 of RG-13022 is 5 µM. RG-13022 inhibits colony formation and DNA synthesis by HER 14 cells, which are stimulated by 50 ng/mL EGF, in a dose-dependent manner. The IC50 for RG-13022 is 1 µM for HER 14 colony formation and 3 µM for HER 14 DNA synthesis. RG-13022 also suppresses colony formation and DNA synthesis by EGF-stimulated MH-85 cells in a dose-dependent manner. The IC50 for RG-13022 on MH-85 cells is 7 µM for colony formation and 1.5 µM for DNA synthesis.. |
| In vivo |
RG-13022 (400 µg/mouse/day) significantly inhibits MH-85 tumour growth. Because of slower tumour growth, MH-85 tumour-bearing animals receiving injections of RG-13022 show less cachexia and hypercalcaemia, eat more food, and are more active than untreated MH-85 tumour-bearing animals. As a result of suppression of tumour growth, RG-13022 prolongs the life span of MH-85 tumour-bearing animals. Administration of mAb108 i.p. (1 mg/mouse/day) at 1, 5, and 10 days after MH-85 inoculation of RG-13022 (400 µg/mouse/day) for 14 days profoundly inhibits MH-85 growth in nude mice.. |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.